1-20 of 29
Lijuan Chen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Response and Safety of Selinexor with VRD Regimen in Newly Diagnosed Multiple Myeloma (NDMM) with Extramedullary Disease (EMD): A Prospective, Open-Label, Multicenter, Phase 2 Study

Yuanyuan Jin, Jianyong Li, Lijuan Chen
Journal: Blood
Blood (2023) 142 (Supplement 1): 6729.
https://doi.org/10.1182/blood-2023-179890
Published: 2023
Journal Articles

Ixazomib Maintenance Therapy in Chinese Patients with Newly Diagnosed Multiple Myeloma Not Treated with Stem Cell Transplantation: A Single-Arm, Open-Label Study

Weijun Fu, Juan Du, Lu Zhong, Lijuan Chen, Jian Li, Donghua Zhang, Jianqing Mi, Yan Liu, Sheng Wu, Richard Labotka, Cong Li, Wenhan Jiang, Wenming Chen
Journal: Blood
Blood (2023) 142 (Supplement 1): 6735.
https://doi.org/10.1182/blood-2023-181444
Published: 2023
Journal Articles

Survival Trends and Prognostic Factors of Patients with Newly Diagnosed Multiple Myeloma Accompanied with Extramedullary Disease

Jing Wang, Na Shen, Xuxing Shen, Run Zhang, Yuan Jin, Jianyong Li, Lijuan Chen
Journal: Blood
Blood (2023) 142 (Supplement 1): 4732.
https://doi.org/10.1182/blood-2023-178373
Published: 2023
Journal Articles

Flonoltinib, a Novel JAK2/FLT3 Inhibitor, Potently Treats Hemophagocytic Lymphohistiocytosis and Increases Sensitivity to Dexamethasone

Ailin Zhao, Xin Wang, Mengshi Hu, Lijuan Chen, Ting Niu
Journal: Blood
Blood (2022) 140 (Supplement 1): 2624–2625.
https://doi.org/10.1182/blood-2022-169258
Published: 2022
Journal Articles

Phase 1 Safety and Dose Escalation of Purinostat Mesylate, a Uniquely Potent and Selective Inhibitor of HDAC I and IIb in Relapsed or Refractory Lymphoma and Multiple Myeloma

Jie Wang, He Li, Linyu Yang, Ailin Zhao, Peng Zhao, Jishi Wang, Jin Xiang, Jia Miao, Li Zheng, Yongsheng Wang, Lijuan Chen, Ting Niu
Journal: Blood
Blood (2022) 140 (Supplement 1): 6612–6613.
https://doi.org/10.1182/blood-2022-167079
Published: 2022
Journal Articles

Clinical Significance and Molecular Characteristics of Circulating Plasma Cells in Multiple Myeloma

Yuan Xia, Run Zhang, Yuanyuan Jin, Qinglin Shi, Yujie Wu, Jianyong Li, Lijuan Chen
Journal: Blood
Blood (2022) 140 (Supplement 1): 10015–10016.
https://doi.org/10.1182/blood-2022-166622
Published: 2022
Journal Articles

Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up

Jian-Qing Mi, Wanhong Zhao, Hongmei Jing, Weijun Fu, Jianda Hu, Lijuan Chen, Yiwen Zhang, Dan Yao, Hui Li, Jordan M Schecter, Fan Yang, Huabin Sun, Sen Hong Zhuang, Da Xu, Tracy Luo, Xiaohu Fan, Ting Niu, Jie Jin, Sai-Juan Chen
Journal: Blood
Blood (2022) 140 (Supplement 1): 7542–7544.
https://doi.org/10.1182/blood-2022-159185
Published: 2022
Journal Articles

A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Chunrui Li, Di Wang, Yongping Song, Jianyong Li, He Huang, Bing Chen, Jing Liu, Kai Hu, Hanyun Ren, Xi Zhang, Zhenyu Li, Dehui Zou, Qingsong Yin, Lijuan Chen, Yongxian HU, Yong Xu, Qian Cheng, Yuelu Guo, Yujun Dong, Li Gao, Aining Xu, Songbai Cai, Wen Wang, Ming Wu, Jue Wang, Liting Chen, Jianfeng Zhou, Lugui Qiu
Journal: Blood
Blood (2021) 138 (Supplement 1): 547.
https://doi.org/10.1182/blood-2021-152576
Published: 2021
Journal Articles

Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)

Lugui Qiu, Weijun Fu, Zhongjun Xia, Zhengzheng Fu, Wenming Chen, Chunkang Chang, Baijun Fang, Gang An, Yongqiang Wei, Zhen Cai, Sujun Gao, Jianyu Weng, Lijuan Chen, Hongmei Jing, Li Fei, Zhuogang Liu, Xiequn Chen, Jing Liu, Yang Yu, Aihua Wang, Yijun Yang, Zhinuan Yu, Kevin Lynch
Journal: Blood
Blood (2021) 138 (Supplement 1): 4770.
https://doi.org/10.1182/blood-2021-145282
Published: 2021
Journal Articles

ATG-010 Plus Low-Dose Dexamethasone (Sd) in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Received Chimeric Antigen Receptor T-Cell (CAR-T)

Weijun Fu, Lugui Qiu, Zhongjun Xia, Zhengzheng Fu, Wenming Chen, Chunkang Chang, Baijun Fang, Gang An, Yongqiang Wei, Zhen Cai, Sujun Gao, Jianyu Weng, Lijuan Chen, Hongmei Jing, Li Fei, Zhuogang Liu, Xiequn Chen, Jing Liu, Yang Yu, Aihua Wang, Zhinuan Yu, Yijun Yang, Kevin Lynch
Journal: Blood
Blood (2021) 138 (Supplement 1): 4778.
https://doi.org/10.1182/blood-2021-146784
Published: 2021
Journal Articles

CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction

Dongzheng Gai, MD, Stewart JP, Xuxing Shen, Jin-Ran Chen, PhD, Can Li, MD, Bailu Peng, PhD, Ya-Wei Qiang, MD PhD, Shmuel Yaccoby, PhD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, Guido J. Tricot, MD PhD, Lijuan Chen, MDPhD, John Shaughnessy, Jr., PhD, Fenghuang Zhan, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21.
https://doi.org/10.1182/blood-2020-140568
Published: 2020
Journal Articles

Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor

Jin Lu, Weijun Fu, MDPhD, Wei Li, MD, Jianda Hu, MDPhD, Gang An, MD PhD, Yafei Wang, Chengcheng Fu, Lijuan Chen, MDPhD, Jie Jin, MD PhD, Xinan Cen, Zheng Ge, MDPhD, Zhen Cai, MD PhD, Ting Niu, MD PhD, Andrew Spencer, DM, Katja Weisel, MD, María-Victoria Mateos, MD PhD, Ajay Nooka, MDMPH, Ming Qi, MD PhD, Steven Sun, Xue Gai, Weiping Liu, Xue Yang, Xiaojun Huang
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–41.
https://doi.org/10.1182/blood-2020-136108
Published: 2020
Journal Articles

Comprehensive Geriatric Assessment in Consecutive Newly-Diagnosed Elderly Multiple Myeloma Patients in China: A Multicentered, Prospective, Non-Interventional Study

Yuan Yao, Dehui Zou, Aijun Liao, Xiaoxia Chu, Wei Wang, Xinan Cen, Lijuan Chen, MD PhD, Li Bao, Rong Fu, Jr., PhD, Hui Liu, Chunyan Sun, MD PhD, Luqun Wang, MD, Fengyan Jin, MD PhD, Hua Yan, Chenglu Yuan, Liangming Ma, Guangxun Gao, Jinqiao Zhang, MD, Da Gao, MD, Jianda Hu, PhD, Jianxia He, Ai-lin Zhao, Lu Zhang, MD, Dao-Bin Zhou, Jian Li, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5493.
https://doi.org/10.1182/blood-2019-125447
Published: 2019
Journal Articles

Dynamic Analysis of Cytokine Profile for Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Cell Therapy

Shuangshuang Yang, MD, Lijuan Chen, MD PhD, Jie Xu, MD PhD, Frank Xiao-Hu Fan, MD PhD, Sun Yan, PhD, Wen Wu, MD PhD, Yan Wang, MD, Jin Wang, MD PhD, Shiwei Jin, MD, Yuebo Zhou, Yuanfang Liu, MD PhD, Yan Zhuang, PhD, Wu Zhang, PhD, Jun-Min Li, Jian Hou, PhD MD, Jian-Yong Li, MD PhD, Zhu Chen, PhD, Jian-Qing Mi, MD PhD, Sai-Juan Chen, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5617.
https://doi.org/10.1182/blood-2019-131799
Published: 2019
Journal Articles

Prognostic Value of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma

Lijuan Chen, MD PhD, Jianyong Li, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1808.
https://doi.org/10.1182/blood-2019-123982
Published: 2019
Journal Articles

Updated Phase 1 Results of a First-in-Human Open-Label Study of Lcar-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (Bcma)

Lijuan Chen, MD PhD, Jie Xu, MD PhD, Weijun Fu, Sr., MD PhD, Shiwei Jin, MD, Shuangshuang Yang, MD, Sun Yan, PhD, Wen Wu, MD PhD, Yuanfang Liu, MD PhD, Wu Zhang, PhD, Xiangqin Weng, Yan Wang, MD, Jin WANG, MD PhD, Xiaoyi Ding, Biao Li, Jiang Zhu, MD, Zhu Chen, PhD, Frank Xiao-Hu Fan, MD PhD, Jianyong Li, MD PhD, Jian Hou, PhD MD, Sai-Juan Chen, PhD, Jian-Qing Mi, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1858.
https://doi.org/10.1182/blood-2019-130008
Published: 2019
Journal Articles

Expression of CRBN Signaling Pathway Proteins Assessed By Immunohistochemical Staining As Candidate Biomarkers for Outcome in Myeloma Patients Treated with IMiDs

Lijuan Chen, MD PhD, Qinglin Shi, MBBS, Rong Wang, MD, Xiupan Lu, MBBS, Yan Gu, MD, Xuxing Shen, MBBS, Xiaoyan Qu, MD PhD, Jianyong Li, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1909.
https://doi.org/10.1182/blood-2018-99-118533
Published: 2018
Journal Articles

Correlation Analysis Between Serum Lactate Dehydrogenase and Prognosis in Old New Diagnosed Multiple Myeloma Patients

Yahui Yuan, Yan Gu, Xiaoyan Qu, PhD, Qinglin Shi, Hua Bai, Ji Xu, Jiadai Xu, Jianyong Li, Lijuan Chen, PhD
Journal: Blood
Blood (2016) 128 (22): 5637.
https://doi.org/10.1182/blood.V128.22.5637.5637
Published: 2016
Journal Articles

Clarithromycin Interacts with Lenalidomide in the Combination Regimen Bird and Overcomes Drug Resistance in Multiple Myeloma

Fengyan Jin, MD PhD, Shuang Li, MD, Lijuan Chen, PhD, Chuan Wu, MD, Wei Li, MD, Jian Hou, MD, Yun Dai, MD PhD
Journal: Blood
Blood (2016) 128 (22): 2125.
https://doi.org/10.1182/blood.V128.22.2125.2125
Published: 2016
Journal Articles

Clinical Analysis of Thromboembolism Associated with Lenalidomide-Based Regimens for Multiple Myeloma Patients

Xiaoyan Qu, PhD, Yan Gu, PhD, Jianyong Li, MD PhD, Lijuan Chen, PhD
Journal: Blood
Blood (2015) 126 (23): 5368.
https://doi.org/10.1182/blood.V126.23.5368.5368
Published: 2015